Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 475-483

  Bramlage, Peter ^a   Zemmrich, Claudia ^a   Ketelhut, Reinhard ^b   Wolf, Wolf Peter ^c   Fronk, Eva Maria ^c   Schmieder, Roland E ^d  

^a Institut fur Pharmakologie und Praventive Medizin   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DAIICHI SANKYO CO   (Japan)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Administration; Antihypertensive agents; Blood pressure; Dosage; Physical activity

Indexed keywords

CREATININE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; OLMESARTAN; POTASSIUM;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; COMPARATIVE EFFECTIVENESS; COUGHING; CREATININE BLOOD LEVEL; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENERGY COST; ESSENTIAL HYPERTENSION; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; POTASSIUM BLOOD LEVEL; PRURITUS;

ADMINISTRATION; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSAGE; PHYSICAL ACTIVITY;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AUSTRIA; BLOOD PRESSURE; DIURETICS; DRUG COMBINATIONS; ENERGY METABOLISM; FEMALE; GERMANY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOTOR ACTIVITY; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84889771603     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S49118     Document Type: Article

References (31)

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. June 14, 2013. [Epub ahead of print.]
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9):1751-1762.
3. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121-2158.
4. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568):1208-1219.
5. Bramlage P. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother. 2009;10(11): 1755-1767.
6. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17(3):252-259.
7. Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. J Clin Hypertens (Greenwich). 2009;11(8):411-421.
8. Kereiakes DJ, Neutel JM. Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus. Drugs R D. 2011;11(3):251-257.
9. Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs. 2007;7(5):361-372.
10. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich). 2008;10(12):911-921.
11. Rump LC, Girerd X, Sellin L, Stegbauer J. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J Hum Hypertens. 2011;25(9):565-574.
12. Narkiewicz K. Angiotensin II receptor blocker combinations: from guidelines to clinical practice. Blood Press. 2012;21(2):73-81.
13. Pescatello LS, Franklin BA, Fagard R, et al. American College of Sports Medicine position stand. Exercise and hypertension. Med Sci Sports Exerc. 2004;36(3):533-553.
14. Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension. 2005;46(4):667-675.
15. James WPT, Schofield EC. Human Energy Requirements. A Manual for Planners and Nutritionists. New York, NY: Oxford University Press; 1990.
16. Ruilope LM. Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension. Vasc Health Risk Manag. 2008;4(6):1237-1248.
17. Rump LC, Sellin L. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide. Expert Opin Pharmacother. 2010;11(13):2231-2242.
18. Punzi HA. Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination. Integr Blood Press Control. 2011;4:73-83.
19. Oparil S, Pimenta E. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex. J Clin Hypertens (Greenwich). 2010;12(1):3-13.
20. Germino FW, Neutel JM, Dubiel R, Maa JF, Chavanu KJ. Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension. Am J Cardiovasc Drugs. 2012;12(5):325-333.
21. Blacher J, Staessen JA, Girerd X, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med. 2000;160(8):1085-1089.
22. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588-2605.
23. Fogari R, Taddei S, Holm-Bentzen M, Baszak J, Melani L, Schumacher K. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Clin Drug Investig. 2010;30(9):581-597.
24. Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F. Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2007;9(1):45-48.
25. Neutel JM, Kereiakes DJ, Waverczak WF, Stoakes KA, Xu J, Shojaee A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin. 2010;26(3):721-728.
26. Scholze J, Schaefer A, Kreutz R. Safety and efficacy of olmesartan: an observational pooled-analysis of 156, 682 hypertensive patients. Expert Opin Drug Saf. 2011;10(2):185-196.
27. Fossum E, Gleim GW, Kjeldsen SE, et al. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. J Intern Med. 2007;262(4):439-448.
28. Fagard RH. The role of exercise in blood pressure control: supportive evidence. J Hypertens. 1995;13(11):1223-1227.
29. Garcia-Ortiz L, Grandes G, Sanchez-Perez A, et al. Effect on cardiovascular risk of an intervention by family physicians to promote physical exercise among sedentary individuals. Rev Esp Cardiol. 2010;63(11): 1244-1252.
30. Ketelhut RG, Franz IW, Scholze J. Regular exercise as an effective approach in antihypertensive therapy. Med Sci Sports Exerc. 2004; 36(1):4-8.
31. Chapman J, Qureshi N, Kai J. Effectiveness of physical activity and dietary interventions in South Asian populations: a systematic review. Br J Gen Pract. 2013;63(607):104-114.